再生医学市场－全球产业规模、份额、趋势、机会和预测（按疗法、材料、应用、最终用户、地区和竞争细分，2020-2030 年）

2024年全球再生医学市场规模达146.7亿美元，预计在预测期内将显着成长，到2030年复合年增长率将达到9.45%。再生医学是一门新兴学科，专注于修復或再生受损的人体器官或组织。这种治疗方法利用干细胞来恢復无法自我疗癒的组织和器官的功能。

例如，根据美国癌症协会的估计，2023 年美国报告的新癌症病例约为 1,958,310 例，癌症相关死亡人数约为 609,820 人，这推动了市场的成长。科学家预计，这种疗法将使器官和组织能够在实验室中生长，然后可以安全地植入人体内。再生医学的需求正在迅速增长，因为它的个人化治疗方法与传统治疗方法相比，可以更有效地管理病情。再生医学涵盖一系列医疗技术，包括人造器官、细胞疗法和组织工程。组织工程和生物材料采用植入体内的支架来促进新组织的形成。这些支架吸引干细胞，促进具有所需形状的组织发育。细胞疗法利用来自牙髓、脂肪、骨骼肌、血液、骨髓和其他来源的干细胞来修復体内受损的组织。医疗设备和人造器官为体内衰竭的器官提供支持。

关键市场驱动因素

增加研发活动投资

主要市场挑战

缺乏可靠的细胞和基因治疗载体生产

主要市场趋势

新兴经济体潜力增强

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球再生医学市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依疗法（干细胞疗法、基因疗法、组织工程、小分子和生物製剂）
  • 依材料（合成材料、生物衍生材料、基因工程材料及药品）
  • 依应用（心血管、肿瘤、肌肉骨骼、伤口癒合、眼科等）
  • 按最终用户（医院、专科中心、学术和研究机构）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美再生医学市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲再生医学市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第八章：亚太再生医学市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美洲再生医学市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东与非洲再生医学市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

第 13 章：全球再生医学市场：SWOT 分析

第 14 章：竞争格局

• Stryker Corporation
• Athersys, Inc.
• Integra Lifesciences Corporation
• Isto Biologics (Isto Biologics Medical Systems, Inc.)
• Organogenesis Inc.
• CryoLife, Inc.
• Medtronic plc
• US Stem Cell, Inc.
• Zimmer Biomet Holdings, Inc.
• 3M Company

第 15 章：策略建议

第16章调查会社について・免责事项

Global Regenerative Medicine Market was valued at USD 14.67 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 9.45% through 2030F. Regenerative medicine is an emerging discipline that focuses on the replacement or regeneration of damaged human organs or tissues. This therapeutic approach utilizes stem cells to restore function to tissues and organs that are unable to heal themselves.

For instance, according to estimates from the American Cancer Society, approximately 1,958,310 new cancer cases and 609,820 cancer-related deaths were reported in the U.S. in 2023, driving growth in the market. Scientists anticipate that this therapy will enable the laboratory growth of organs and tissues, which can then be safely implanted into the human body. The demand for regenerative medicine is rapidly increasing due to its personalized treatment approach, which provides more effective management of conditions compared to conventional treatments. Regenerative medicine encompasses a range of medical techniques, including artificial organs, cellular therapies, and tissue engineering. Tissue engineering and biomaterials employ scaffolds that are implanted in the body to facilitate the formation of new tissue. These scaffolds attract stem cells, promoting the development of tissue with the desired shape. Cellular therapies utilize stem cells derived from dental pulp, fat, skeletal muscle, blood, bone marrow, and other sources to repair damaged tissues within the body. The medical devices and artificial organs offer support to failing organs within the body.

Key Market Drivers

Increasing Investments in R&D Activities

Increasing investments in research and development (R&D) activities have propelled market growth by driving innovative product launches. This surge in investments has led to comprehensive R&D initiatives, with numerous start-up companies receiving funding for the development of novel therapies and products. Consequently, this has facilitated significant collaborations, mergers, and partnerships aimed at maximizing the mutual benefits of R&D activities. In June 2022, Galapagos, a Belgian biotech company, announced its acquisition of Cell Point and Abound Bib. This strategic move aims to expedite the development and commercialization of next-generation cell therapies. With the integration of Cell Point and Abound Bio, Galapagos will gain access to innovative, scalable, decentralized, and automated point-of-care cell therapy supply models, as well as a cutting-edge fully human antibody-based therapeutics platform. Together, these advancements position Galapagos as a fully integrated biopharmaceutical company with the potential to disrupt the CAR-T treatment paradigm. Apart from private entities, various governments and government-funded research institutes are actively investing in this industry to introduce effective treatment options for chronic diseases like cancer, Parkinson's disease, diabetes, renal diseases, cardiovascular diseases, and others. In January 2022, the Royal College of Surgeons in Ireland secured USD 226,000 in funding from the European Commission for the development of antioxidant-ion substituted nanoparticles for osteoporotic bone treatment.

Key Market Challenges

Lack of Reliable Vector Production for Cell and Gene Therapy

Current methods of vector production often have limitations in terms of scalability. Producing enough high-quality vectors to meet the demands of clinical trials and potential commercialization can be challenging, especially for therapies with large patient populations. As regenerative medicine advances, the diversity of therapeutic approaches and vector types increases. Developing reliable vector production methods for various vectors, including adeno-associated viruses (AAVs) and lentiviruses, is crucial to accommodate this diversity.

Key Market Trends

Increase In Potential in Emerging Economies

Developing economies hold significant potential in the regenerative medicine market, driven by the rising prevalence of traumatic injuries and organ transplantations worldwide. Key industry players have strategically analyzed the opportunities in tissue engineering and regenerative medicine within these economies, leveraging various developmental strategies such as product launches, approvals, agreements, partnerships, and mergers. Despite ethical challenges arising from unfavorable norms, it is anticipated that developing economies will embrace tissue-engineering and regeneration technology.

Key Market Players

• Stryker Corporation
• Athersys, Inc.
• Integra Lifesciences Corporation
• Isto Biologics (Isto Biologics Medical Systems, Inc.)
• Organogenesis Inc.
• CryoLife, Inc.
• Medtronic plc
• U.S. Stem Cell, Inc.
• Zimmer Biomet Holdings, Inc.
• 3M Company

Report Scope:

In this report, the Global Regenerative Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Regenerative Medicine Market, By Therapy:

• Stem Cell Therapy
• Gene Therapy
• Tissue Engineering
• Small Molecule & Biologic

Regenerative Medicine Market, By Material:

• Synthetic Material
• Biologically Derived Material
• Genetically Engineered Material
• Pharmaceuticals

Regenerative Medicine Market, By Application:

• Cardiovascular
• Oncology
• Musculoskeletal
• Wound Healing
• Ophthalmology
• Others

Regenerative Medicine Market, By End User:

• Hospitals
• Specialty Centres
• Academic & Research Institutes

Regenerative Medicine Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Regenerative Medicine Market.

Available Customizations:

Global Regenerative Medicine market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Regenerative Medicine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy (Stem Cell Therapy, Gene Therapy, Tissue Engineering, And Small Molecule & Biologic)
  • 5.2.2. By Material (Synthetic Material, Biologically Derived Material, Genetically Engineered Material, And Pharmaceuticals)
  • 5.2.3. By Application (Cardiovascular, Oncology, Musculoskeletal, Wound Healing, Ophthalmology, And Others)
  • 5.2.4. By End User (Hospitals, Specialty Centres, Academic & Research Institutes)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Regenerative Medicine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy
  • 6.2.2. By Material
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Regenerative Medicine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy
      • 6.3.1.2.2. By Material
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Regenerative Medicine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy
      • 6.3.2.2.2. By Material
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Regenerative Medicine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy
      • 6.3.3.2.2. By Material
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Regenerative Medicine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy
  • 7.2.2. By Material
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Regenerative Medicine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy
      • 7.3.1.2.2. By Material
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Regenerative Medicine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy
      • 7.3.2.2.2. By Material
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Regenerative Medicine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Therapy
      • 7.3.3.2.2. By Material
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. France Regenerative Medicine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy
      • 7.3.4.2.2. By Material
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Regenerative Medicine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy
      • 7.3.5.2.2. By Material
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia-Pacific Regenerative Medicine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy
  • 8.2.2. By Material
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Regenerative Medicine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy
      • 8.3.1.2.2. By Material
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Regenerative Medicine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy
      • 8.3.2.2.2. By Material
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Regenerative Medicine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy
      • 8.3.3.2.2. By Material
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Regenerative Medicine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy
      • 8.3.4.2.2. By Material
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Regenerative Medicine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy
      • 8.3.5.2.2. By Material
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. South America Regenerative Medicine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy
  • 9.2.2. By Material
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Regenerative Medicine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy
      • 9.3.1.2.2. By Material
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Regenerative Medicine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy
      • 9.3.2.2.2. By Material
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Regenerative Medicine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy
      • 9.3.3.2.2. By Material
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. Middle East and Africa Regenerative Medicine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy
  • 10.2.2. By Material
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Regenerative Medicine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy
      • 10.3.1.2.2. By Material
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Regenerative Medicine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy
      • 10.3.2.2.2. By Material
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Regenerative Medicine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy
      • 10.3.3.2.2. By Material
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

13. Global Regenerative Medicine Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Stryker Corporation
• 14.2. Athersys, Inc.
• 14.3. Integra Lifesciences Corporation
• 14.4. Isto Biologics (Isto Biologics Medical Systems, Inc.)
• 14.5. Organogenesis Inc.
• 14.6. CryoLife, Inc.
• 14.7. Medtronic plc
• 14.8. U.S. Stem Cell, Inc.
• 14.9. Zimmer Biomet Holdings, Inc.
• 14.10. 3M Company

15. Strategic Recommendations

16. About Us & Disclaimer